Evidence map›Paper›PMID 35062310›Full record

ArticleViruses2022

The

Lorena Urda, Matthias Heinrich Kreuter, Jürgen Drewe, Georg Boonen, Veronika Butterweck, Thomas Klimkait

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Viruses · 2026
    Article
  2. Efficacy and Safety ofAdvances in respiratory medicine · 2025
    Review
  3. Bioactive natural products in COVID-19 therapy.Frontiers in pharmacology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Lorena UrdaDepartment Biomedicine, University of Basel, Petersplatz 10, 4051 Basel, Switzerland.
Matthias Heinrich KreuterMedical Department, Max Zeller & Söhne AG, Seeblickstrasse 4, 8590 Romanshorn, Switzerland.
Jürgen DreweMedical Department, Max Zeller & Söhne AG, Seeblickstrasse 4, 8590 Romanshorn, Switzerland.ORCID 0000-0001-5178-7825
Georg BoonenMedical Department, Max Zeller & Söhne AG, Seeblickstrasse 4, 8590 Romanshorn, Switzerland.
Veronika ButterweckMedical Department, Max Zeller & Söhne AG, Seeblickstrasse 4, 8590 Romanshorn, Switzerland.
Thomas KlimkaitDepartment Biomedicine, University of Basel, Petersplatz 10, 4051 Basel, Switzerland.ORCID 0000-0003-4945-6511
Max Zeller Söhne (Switzerland) · CHUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19), caused by a novel coronavirus (SARS-CoV-2), has spread worldwide, affecting over 250 million people and resulting in over five million deaths. Antivirals that are effective are still limited. The antiviral activities of the

Indexed as

Adenosine MonophosphateAlanineAnimalsAntiviral AgentsCarbon DioxideCell SurvivalChlorocebus aethiopsDose-Response Relationship, DrugGenetic VariationPetasitesPlant ExtractsSARS-CoV-2SesquiterpenesVero CellsVirus ReplicationAdenosine MonophosphateAlanineAntiviral AgentsCarbon DioxideisopetasinpetasinPlant ExtractsremdesivirSesquiterpenesZe 339anti-COVID-19antiviralCOVID-19cytotoxicityDelta variantisopetasinPetasites hybridusSARS-CoV-2selectivity index

Identifiers

PMID35062310
PMCPMC8781559
OpenAlexW4220784482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.